Stock Code: 4771

VIZIONFOCUS INC. and subsidiaries

Consolidated Financial Statements and Independent Auditors' Review Report

Q1 of 2026 and 2025

Address: 3F, No. 66, Youyi Road, Zhunan Township,
Miaoli County
Tel: (037) 582900

Independent Auditors' Review Report

To VIZIONFOCUS INC.:

Foreword

The consolidated balance sheets of VIZIONFOCUS INC. and its subsidiaries as of March 31, 2026 and 2025, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months ended March 31, 2026 and 2025, together with the notes to the consolidated financial statements (including a summary of significant accounting policies), have been reviewed by us. The preparation of consolidated financial statements that present fairly the Company's consolidated financial position, financial performance, and cash flows in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission is the responsibility of the Company's management. Our responsibility is to express a conclusion on these consolidated financial statements based on our review.

Scope

We conducted our review in accordance with International Standard on Review Engagements No. 2410 "Review of Financial Statements." The procedures performed in a review of consolidated financial statements consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Therefore, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of VIZIONFOCUS INC. and its subsidiaries as of March 31, 2026 and 2025, and their consolidated financial performance and consolidated cash flows for the three months ended March 31, 2026 and 2025, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IAS 34, "Interim Financial Reporting," as endorsed and issued into effect by the Financial Supervisory Commission.

The engagement partners on the reviews resulting in this independent auditors' review report are Hsiu-Wen Chen and Yao-Lin Huang.

Deloitte & Touche
Taipei, Taiwan
Republic of China

May 11, 2026

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' review report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' review report and consolidated financial statements shall prevail.

VIZIONFOCUS INC. and subsidiaries
Consolidated Balance Sheet
March 31, 2026, December 31, 2025 and March 31, 2025

Unit: NTD Thousand

Code	Assets	March 31, 2026 Amount	%	December 31, 2025 Amount	%	March 31, 2025 Amount	%
	Current assets						
1100	Cash and cash equivalents (Note 6)	$ 939,697	13	$ 989,443	15	$ 1,294,075	20
1150	Notes receivable (Note 8)	8,207	-	11,965	-	3,072	-
1170	Accounts receivable (Note 8 & 29)	938,185	13	879,873	12	647,800	10
1200	Other receivables	7,502	-	2,051	-	10,720	-
1220	Current income tax assets	33,810	-	14,130	-	10,380	-
130X	Inventories (Note 9)	380,486	5	360,698	5	294,083	5
1410	Prepayments	111,295	1	98,576	1	63,481	1
1476	Other financial assets – current (Note 7 & 30)	240,820	3	299,728	4	329,432	5
1479	Other current assets	2,211	-	1,972	-	254	-
11XX	Total current assets	2,662,213	35	2,658,436	37	2,653,297	41
	Non-current assets						
1600	Property, plant and equipment (Notes 11, 29 & 30)	4,017,717	55	3,725,697	54	3,152,278	51
1755	Right-of-use assets (Note 12)	296,743	4	303,888	4	354,227	6
1780	Intangible assets (Note 13)	163,174	2	159,686	2	131,802	2
1840	Deferred income tax assets	12,147	-	10,548	-	7,614	-
1915	Prepayment for equipment (Note 29)	269,043	4	189,403	3	31,701	-
1920	Refundable deposits (Note 29)	18,176	-	13,452	-	12,882	-
15XX	Total non-current assets	4,777,000	65	4,402,674	63	3,690,504	59
1XXX	Total assets	$ 7,439,213	100	$ 7,061,110	100	$ 6,343,801	100
Code	Liabilities and equity						
	Current liabilities						
2100	Short-term borrowings (Note 14)	$ -	-	$ 20,000	-	$ -	-
2130	Contract liabilities – Current (Note 19)	16,375	-	21,318	-	7,931	-
2150	Notes payable (Note 15)	-	-	3,014	-	-	-
2170	Accounts payable (Note 15)	278,377	4	250,187	4	197,550	3
2200	Other payables (Note 16 & 29)	431,441	6	479,658	7	343,715	5
2230	Current income tax liabilities	135,322	2	76,121	1	108,566	2
2280	Lease liabilities – current (Notes 12 & 29)	53,376	1	52,301	1	50,088	1
2313	Deferred revenue (Note 14 & 24)	3,076	-	3,319	-	4,017	-
2322	Long-term borrowings due within one year (Note 14 & 30)	114,942	2	136,685	2	155,279	2
2399	Other current liabilities	4,026	-	1,524	-	207	-
21XX	Total current liabilities	1,036,935	15	1,044,127	15	867,353	13
	Non-current liabilities						
2540	Long-term borrowings (Note 14 & 30)	1,180,020	16	1,114,709	17	881,044	15
2570	Deferred income tax liabilities	241,042	3	219,285	3	148,396	2
2580	Lease liabilities – non-current (Notes 12 & 29)	252,283	3	260,143	4	310,819	5
2630	Long-term deferred revenue (Note 14 & 24)	12,648	-	11,755	-	9,102	-
2640	Net defined benefit liabilities (Note 4 & 17)	2,828	-	2,550	-	1,646	-
2670	Other non-current liabilities	5	-	13	-	242	-
25XX	Total non-current liabilities	1,688,826	22	1,608,455	24	1,351,249	22
2XXX	Total liabilities	2,725,761	37	2,652,582	39	2,218,602	35
	Equity attributable to owners of the Company (Note 18)						
3110	Common stock capital	587,087	8	585,277	8	580,447	9
3200	Capital reserve	1,863,668	25	1,851,365	26	1,841,333	29
	Retained earnings						
3310	Statutory Reserve	149,592	2	149,592	2	82,650	1
3320	Special reserves	-	-	-	-	9,499	-
3350	Undistributed earnings	1,583,596	21	1,368,819	19	1,201,202	19
3300	Total retained earnings	1,733,188	23	1,518,411	21	1,293,351	20
3400	Other equity						
3410	Foreign Currency Translation Adjustment	67,151	1	29,448	-	41,371	1
31XX	Total owners' equity of the Company	4,251,094	57	3,984,501	55	3,756,502	59
36XX	Non-controlling interests (Note 10 & 18)	462,358	6	424,027	6	368,697	6
3XXX	Total equity	4,713,452	63	4,408,528	61	4,125,199	65
3X2X	Total liabilities and equity	$ 7,439,213	100	$ 7,061,110	100	$ 6,343,801	100

The accompanying notes are an integral part of the consolidated financial statements.

VIZIONFOCUS INC. and subsidiaries
Consolidated Statement of Comprehensive Income
For the three months ended March 31, 2026 and 2025

Unit: NT$ thousand, except for earnings per share

Code		January 1 to March 31, 2026 Amount	%	January 1 to March 31, 2025 Amount	%
4000	Net operating revenue (Note 19 & 29)	$ 1,030,727	100	$ 810,535	100
5000	Operating costs (Note 9, 20 & 29)	608,199	59	474,747	59
5900	Gross operating profit	422,528	41	335,788	41
	Operating expenses (Note 8 & 20)				
6100	Sales promotion expenses	37,557	4	20,107	2
6200	Administrative expenses	38,637	4	36,757	5
6300	R&D expenses	48,210	4	40,235	5
6450	Expected credit loss	-	-	206	-
6000	Total operating expenses	124,404	12	97,305	12
6900	Net operating profit	298,124	29	238,483	29
	Non-operating income and expenses (Note 20 & 29)				
7100	Interest revenue	2,268	-	3,464	-
7010	Other income	2,725	-	10,191	2
7020	Other gains and losses	13,600	1	10,809	2
7050	Finance Costs	(6,074)	-	(6,675)	(1)
7000	Total non-operating income and expenses	12,519	1	17,789	3
7900	Net income before tax	310,643	30	256,272	32
7950	Income tax expense (Note 4 & 21)	69,136	7	54,956	7
8200	Net income for the period	241,507	23	201,316	25

(To be Continued)

(Continued from previous page)

Code		January 1 to March 31, 2026 Amount	%	January 1 to March 31, 2025 Amount	%
8300	Other comprehensive income (Notes 18 & 21)				
8360	Items that may be reclassified subsequently to profit or loss				
8361	Foreign Currency Translation Adjustment	$ 58,730	6	$ 34,479	4
8399	Income tax related to items that may be reclassified	(9,426)	(1)	(5,524)	(1)
8300	Other comprehensive income for the period (net amount after tax)	49,304	5	28,955	3
8500	Total comprehensive income for the period	$ 290,811	28	$ 230,271	28
	Net profit attributable to				
8610	Owners of the Company	$ 214,777	21	$ 192,731	24
8620	Non-controlling interests	26,730	2	8,585	1
8600		$ 241,507	23	$ 201,316	25
	Total comprehensive income attributable to				
8710	Owners of the Company	$ 252,480	24	$ 214,827	26
8720	Non-controlling interests	38,331	4	15,444	2
8700		$ 290,811	28	$ 230,271	28
	Earnings per share (Note 22)				
9710	Basic	$ 3.66		$ 3.32	
9810	Diluted	$ 3.63		$ 3.27	

The accompanying notes are an integral part of the consolidated financial statements.

VIZIONFOCUS INC. and subsidiaries
Consolidated Statement of Changes in Equity
For the three months ended March 31, 2026 and 2025

Unit: NTD Thousand

Code		Equity attributable to owners of the Company										Non-controlling interests	Total equity
		Capital stock				Retained earnings				Other equity			
		Common stock capital	Advance Receipts for Share Capital	Total	Capital reserve	Statutory Reserve	Special reserves	Undistributed earnings	Total	Foreign Currency Translation Adjustment	Total		
A1	Balance on January 1, 2026	$ 585,277	$ -	$ 585,277	$ 1,851,365	$ 149,592	$ -	$ 1,368,819	$ 1,518,411	$ 29,448	$ 3,984,501	$ 424,027	$ 4,408,528
D1	Net income for the three months ended March 31, 2026	-	-	-	-	-	-	214,777	214,777	-	214,777	26,730	241,507
D3	Other comprehensive income after tax for the three months ended March 31, 2026	-	-	-	-	-	-	-	-	37,703	37,703	11,601	49,304
D5	Total comprehensive income for the three months ended March 31, 2026	-	-	-	-	-	-	214,777	214,777	37,703	252,480	38,331	290,811
N1	Share-based payment transactions (Note 18 & 23)	1,810	-	1,810	12,303	-	-	-	-	-	14,113	-	14,113
Z1	Balance on March 31, 2026	$ 587,087	$ -	$ 587,087	$ 1,863,668	$ 149,592	$ -	$ 1,583,596	$ 1,733,188	$ 67,151	$ 4,251,094	$ 462,358	$ 4,713,452
A1	Balance on January 1, 2025	$ 579,247	$ 5,498	$ 584,745	$ 1,828,095	$ 82,650	$ 9,499	$ 1,008,471	$ 1,100,620	$ 19,275	$ 3,532,735	$ 316,862	$ 3,849,597
D1	Net income for the three months ended March 31, 2025	-	-	-	-	-	-	192,731	192,731	-	192,731	8,585	201,316
D3	Other comprehensive income after tax from January 1 to March 31, 2025	-	-	-	-	-	-	-	-	22,096	22,096	6,859	28,955
D5	Total comprehensive income for the three months ended March 31, 2025	-	-	-	-	-	-	192,731	192,731	22,096	214,827	15,444	230,271
M5	Difference Between the Fair Value and Carrying Amount of the Consideration Paid or Received for the Acquisition or Disposal of Subsidiaries (Note 25)	-	-	-	29	-	-	-	-	-	29	35,571	35,600
N1	Share-based payment transactions (Note 18 & 23)	1,200	(5,498)	(4,298)	13,209	-	-	-	-	-	8,911	-	8,911
O1	Increase of non-controlling interests (Note 18)	-	-	-	-	-	-	-	-	-	-	820	820
Z1	Balance on March 31, 2025	$ 580,447	$ -	$ 580,447	$ 1,841,333	$ 82,650	$ 9,499	$ 1,201,202	$ 1,293,351	$ 41,371	$ 3,756,502	$ 368,697	$ 4,125,199

The accompanying notes are an integral part of the consolidated financial statements.

VIZIONFOCUS INC. and subsidiaries
Consolidated Statements of Cash Flows
For the three months ended March 31, 2026 and 2025

Unit: NTD Thousand

Code		January 1 to March 31, 2026	January 1 to March 31, 2025
	Cash flow from operating activities		
A10000	Net income before tax for the period	$ 310,643	$ 256,272
A20010	Income and expenses		
A20100	Depreciation expense	107,852	94,216
A20200	Amortization expense	4,806	3,709
A20300	Expected credit loss	-	206
A20900	Finance Costs	6,074	6,675
A21200	Interest revenue	(2,268)	(3,464)
A21900	Share-based payment for remuneration	-	680
A22500	Gains from the disposal of property, plant and equipment	-	(25)
A23700	Loss on inventory valuation and obsolescence	3,429	6,470
A29900	Amortization of deferred income	(962)	(1,050)
A29900	Others	397	33
A30000	Net changes in operating assets and liabilities		
A31130	Notes receivable	3,758	5,442
A31150	Accounts receivable	(58,312)	(15,128)
A31180	Other receivables	(5,294)	(8,949)
A31200	Inventories	(23,801)	(12,055)
A31230	Prepayments	(12,719)	(4,033)
A31240	Other current assets	(239)	(39)
A31990	Other non-current assets	-	64
A32125	Contract liabilities	(4,943)	3,547
A32130	Notes payable	(3,014)	-
A32150	Accounts payable	28,190	3,097
A32180	Other payables	(9,160)	(1,691)
A32230	Other current liabilities	2,502	(227)
A32240	Net defined benefit liabilities	278	168
A32990	Other non-current liabilities	(8)	5
A33000	Cash inflow from operations	347,209	333,923
A33100	Interest received	2,111	3,393
A33300	Interest paid	(6,775)	(5,572)
A33500	Income tax paid	(20,932)	(12,112)
AAAA	Net cash inflow from operating activities	321,613	319,632

(To be Continued)

(Continued from previous page)

Code		January 1 to March 31, 2026	January 1 to March 31, 2025
	Cash flow from investing activities		
B02700	Purchase of property, plant and equipment	$ (465,214)	$ (210,682)
B02800	Proceeds from the disposal of property, plant and equipment	-	25
B03700	Increase in refundable deposits	(4,724)	(458)
B04500	Acquisition of intangible assets	(10,578)	(24,995)
B06600	Increase (decrease) of other financial assets	58,908	(75,632)
BBBB	Net cash outflow from investing activities	(421,608)	(311,742)
	Cash flow from financing activities		
C00200	Decrease in short-term borrowings	(20,000)	-
C01600	Borrowing of long-term loans	104,440	101,820
C01700	Repayment of long-term borrowings	(60,222)	(40,483)
C04020	Lease principal repayment	(13,017)	(12,005)
C04800	Exercise of employee stock options	14,113	8,231
C05800	Changes in non-controlling interests	-	35,600
CCCC	Net cash inflow from financing activities	25,314	93,163
DDDD	Effect of exchange rate changes on cash and cash equivalents	24,935	12,896
EEEE	Net increase (decrease) in cash and cash equivalents	(49,746)	113,949
E00100	Opening balance of cash and cash equivalents	989,443	1,180,126
E00200	Closing balance of cash and cash equivalents	$ 939,697	$ 1,294,075

The accompanying notes are an integral part of the consolidated financial statements.

I. Company history

The Company was established in May 2012, mainly engaged in the manufacturing of medical equipment, machinery and equipment, optical instruments, precision instruments and international trading, and other consulting services.

The Company has been listed and traded on the Taiwan Stock Exchange since March 2024.

The consolidated financial statements are presented in the Company's functional currency, NTD.

II. Date and procedure for adopting financial statements

This consolidated financial statement was released after being approved by the Board of Directors on May 11, 2026.

III. Application of new and amended standards and interpretations

(I) The initial application of International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), interpretations (IFRIC), and interpretation announcements (SIC) approved and issued by the Financial Supervisory Commission (referred to as 'IFRS accounting standards').

The application of the amendments to the IFRSs endorsed and issued into effect by the FSC does not have material impact on the Company's and its subsidiaries' accounting policies.

(II) IFRS accounting standards issued by the IASB but not yet endorsed and issued into effect by the FSC

New/amended/revised standards and interpretations	Effective date announced by IASB (Note 1)
Amendments to IFRS 10 and IAS 28 "Sale or Contribution of Assets between an Investor and its Associate or Joint Venture"	To be determined
IFRS 18 "Presentation and Disclosures of Financial Statements"	January 1, 2027 (Note 2)
IFRS 19 "Subsidiary without Public Accountability: Disclosures" (including 2025 amendments)	January 1, 2027
Amendments to IAS 21 "Translation to a Hyperinflationary Presentation Currency"	January 1, 2027

Note 1: Unless stated otherwise, the above new IFRSs are effective for annual periods beginning on or after their respective effective dates.

Note 2: The FSC announced on September 25, 2025 that Taiwan enterprises shall adopt IFRS 18 effective January 1, 2028, with the option to early adopt following FSC recognition of IFRS 18.

IFRS 18 “Presentation and Disclosure in Financial Statements” and relevant consequential amendments

IFRS 18 will replace IAS 1 “Presentation of Financial Statements.” The main changes include:

- The Company and its subsidiaries are required to assess whether they have specified principal business activities of investing in particular types of assets and providing financing to customers, and accordingly classify income and expense items in the statement of profit or loss into the operating, investing, financing, income taxes, and discontinued operations categories.
- The income statement should present operating profit or loss, profit or loss before financing and taxes, as well as subtotals and totals of profit or loss.
- Providing guidance to strengthen aggregation and disaggregation requirements: The Company and its subsidiaries must identify assets, liabilities, equity, income, expenses, and cash flows arising from individual transactions or other events, and classify and aggregate them based on common characteristics, so that each line item presented in the primary financial statements has at least one similar characteristic. Items of dissimilar nature should be presented separately in the primary financial statements and notes. The Company and its subsidiaries shall label items as "other" only when they cannot find more informative labels.
- Enhanced disclosure of management-defined performance measures: When the Company and its subsidiaries communicate publicly outside the financial statements and communicate management's view of a particular aspect of the overall financial performance to users of financial statements, they should disclose information related to management-defined performance measures in a single note to the financial statements, including a description of the measure, how it is calculated, its reconciliation with subtotals or totals specified in IFRS accounting standards, and the income tax and non-controlling interest effects of related reconciling items.

In addition, IAS 7 "Statement of Cash Flows" has been amended with the following consequential modifications:

- When the Company and its subsidiaries prepares cash flows from operating activities using the indirect method, profit or loss from operations shall be used as the starting point for reconciliation.
- Interest and dividends received by the Company and its subsidiaries shall be classified as investing activities, while interest and dividends paid shall be classified as financing activities. If the Company and its subsidiaries are assessed to have specified principal business activities, they must consider the categories under which dividend income, interest income, and interest expense are presented in the statement of profit or loss to determine the classification of dividends received, interest received, and interest paid in the statement of cash flows; however, each of the aforementioned cash flows may be classified under only a single activity in the statement of cash flows.

As of the release date of these consolidated financial statements after the approval of the Board of Directors, the Company and its subsidiaries continue to evaluate the impact of other standards and amendments to interpretations on the financial position and financial performance. The relevant impact will be disclosed when the evaluation is completed.

IV. Summary of significant accounting policies

(I) Compliance Statement

This consolidated financial statement has been prepared in conformity with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IAS 34 "Interim Financial Reporting" as endorsed by the Financial Supervisory Commission. These consolidated financial statements do not include all IFRS disclosures required for full annual consolidated financial statements.

(II) Basis of preparation

Except for the financial instruments measured at fair value and the net defined benefit liabilities recognized based on the present value of the defined benefit obligation less the fair value of plan assets, this consolidated financial statement has been prepared on the basis of historical cost.

The fair value is divided into Level 1 to Level 3 according to the observable degree and importance of the relevant input value:

1. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities available on the measurement date.
2. Level 2 inputs: Inputs, other than quoted prices in Level 1, that are observable, either directly (i.e., prices) or indirectly (i.e., derived from prices) for the asset or liability.
3. Level 3 inputs are unobservable inputs for the asset or liability.

(III) Basis of consolidation

This consolidated financial statement contains the financial statements of the Company and the entities (subsidiaries) controlled by the Company.

The financial statements of the subsidiaries have been adjusted to make their accounting policies consistent with the Company's accounting policies. In preparing the consolidated financial statements, all intra-group transactions, account balances, income, and expenses have been eliminated. The total comprehensive income of subsidiaries is attributed to the owners of the Company and non-controlling interests, even if this results in non-controlling interests carrying a deficit balance.

Changes in the Company's and its subsidiaries' equity in subsidiaries that do not result in a loss of control are accounted for as equity transactions. The book value of the Company's and its subsidiaries' and non-controlling interests have been adjusted to reflect the changes in their relative interests in the subsidiaries. The difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the Company.

For details on subsidiaries, ownership percentages, and business activities, refer to Note 10 and Tables 1 and 2.

(IV) Other significant accounting policies

Except for the following explanations, please refer to the summary of significant accounting policies in the 2025 annual consolidated financial statements.

1. Removal of financial liabilities

Financial liabilities are derecognized on the settlement date, which is the date on which the obligation specified in the contract is discharged, cancelled or expires, or the date on which debt instruments with substantially different terms are exchanged, or the terms of a financial liability are substantially modified.

When derecognizing a financial liability, the difference between the book value and the consideration paid (including any non-cash assets transferred or liabilities assumed) is recognized in profit or loss.

2. Retirement benefits

Interim period pension costs are calculated on a year-to-date basis using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted for significant market volatility, plan amendments, curtailments and other significant one-time events during the interim period, if any.

3. Income tax expense

Income tax expense represents the sum of current income tax and deferred income tax. Interim period income tax expense is accrued based on the estimated average annual effective tax rate applied to the pre-tax income for the interim period.

V. Major sources of uncertainty in major accounting judgments, estimates, and assumptions

The significant accounting judgments, estimates and sources of estimation uncertainty applied in these consolidated financial statements are consistent with those of the 2025 annual consolidated financial statements.

VI. Cash and cash equivalents

	March 31, 2026	December 31, 2025	March 31, 2025
Cash on hands	$ 335	$ 159	$ 160
Checks and demand deposits	924,362	719,284	753,915
Cash equivalents (investment with original maturity date of less than 3 months)			
Time deposits in banks	15,000	170,000	540,000
Commercial paper	-	100,000	-
	$ 939,697	$ 989,443	$ 1,294,075

VII. Other financial assets – current

	March 31, 2026	December 31, 2025	March 31, 2025
Time deposits with original maturity exceeding 3 months	$ 238,205	$ 297,180	$ 327,145
Pledged time deposits (Note 30)	2,615	2,548	2,287
	$ 240,820	$ 299,728	$ 329,432
Interest rate per annum (%)	1.285～1.8	1.35～1.65	1.35～2

VIII. Notes and accounts receivable

	March 31, 2026	December 31, 2025	March 31, 2025
Notes receivable			
Total book value measured at amortized cost - due to operations	$ 8,207	$ 11,965	$ 3,072
Accounts receivable			
Total book value measured at amortized cost	$938,185	$879,873	$649,508
Less: Loss allowance	-	-	1,708
	$938,185	$879,873	$647,800

The Company and its subsidiaries recognize the loss allowance for accounts receivable based on the lifetime expected credit losses. The lifetime expected credit losses are calculated using a provision matrix, which takes into account customers' past collection experience, increase in delayed payments beyond the credit period, industry economic conditions and outlook. If there is evidence indicating that a transaction party is experiencing severe financial difficulties, and the company and its subsidiaries cannot reasonably expect to recover the amounts due—for instance, if the transaction party is undergoing liquidation or the debt has become overdue—the company and its subsidiaries will proceed according to its internal policy for managing abnormal receivables. The relevant receivables are directly written off, although collection efforts will continue. Any amounts recovered through these efforts will be recognized in the profit and loss statement.

The Company and subsidiaries continuously monitor collections to ensure that appropriate actions are taken for the recovery of overdue amounts. Additionally, on the balance sheet date, each receivable's recoverable amount is reviewed to ensure that adequate allowances for doubtful accounts have been provided for receivables that cannot be recovered.

The allowance for losses of accounts receivable measured by the Company and its subsidiaries based on the allowance matrix is as follows:

March 31, 2026

	Not past due	Overdue 1 to 30 days	Overdue 31 to 120 days	Overdue 121 to 360 days	Overdue over 360 days	Counterparty shows signs of default	Total
Expected credit loss rate (%)	-	4	4	4	100	100	
Gross carrying amount	$ 930,172	$ 1,455	$ 14,765	$ -	$ -	$ -	$ 946,392
Allowance for losses (lifetime expected credit losses)	-	-	-	-	-	-	-
Amortized cost	$ 930,172	$ 1,455	$ 14,765	$ -	$ -	$ -	$ 946,392

December 31, 2025

	Not past due	Overdue 1 to 30 days	Overdue 31 to 120 days	Overdue 121 to 360 days	Overdue over 360 days	Counterparty shows signs of default	Total
Expected credit loss rate (%)	-	4	4	4	100	100	
Gross carrying amount	$ 887,151	$ 3,186	$ 1,501	$ -	$ -	$ -	$ 891,838
Allowance for losses (lifetime expected credit losses)	-	-	-	-	-	-	-
Amortized cost	$ 887,151	$ 3,186	$ 1,501	$ -	$ -	$ -	$ 891,838

March 31, 2025

	Not past due	Overdue 1 to 30 days	Overdue 31 to 120 days	Overdue 121 to 360 days	Overdue over 360 days	Counterparty shows signs of default	Total
Expected credit loss rate (%)	-	4	4	4	100	100	
Gross carrying amount	$ 634,094	$ 9,877	$ 7,193	$ -	$ -	$ 1,416	$ 652,580
Allowance for losses (lifetime expected credit losses)	-	(75)	(266)	-	-	(1,367)	(1,708)
Amortized cost	$ 634,094	$ 9,802	$ 6,927	$ -	$ -	$ 49	$ 650,872

Information on changes in loss allowance of accounts receivable is as follows:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Opening balance	$ -	$ 1,473
Current period provision	-	206
Exchange rate effect	-	29
Closing balance	$ -	$ 1,708

IX. Inventories

	March 31, 2026	December 31, 2025	March 31, 2025
Raw materials	$ 75,614	$ 62,401	$ 59,142
Materials	56,675	37,828	36,340
Work in process	59,002	56,960	44,945
Semi-finished product	5,551	4,730	7,566
Finished goods	141,969	165,240	134,260
Merchandise	41,675	33,539	11,830
	$380,486	$360,698	$294,083

The components of the operating cost are as follows:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Cost of goods sold	$ 606,312	$ 470,413
Loss on inventory valuation and obsolescence	3,429	6,470
Income from sale of scraps and scraps	(1,939)	(2,169)
Others	397	33
	$ 608,199	$ 474,747

X. Subsidiary

(I) Subsidiaries included in the consolidated financial statements

The entities in the consolidated financial statements are as follows:

Name of Investment Company	Name of subsidiary	Nature of business	Percentage of equity held			Description
			March 31, 2026	December 31, 2025	March 31, 2025	
The Company	Green Wealth Investments Limited (Green Wealth)	International investment	100	100	100	
The Company	Star Focus Inc. (Star Focus)	Medical device sales	40.67	40.67	40.67	Note 1
The Company	Optical Connection Technology Inc. (OCTI)	Medical device sales	98.77	98.77	98.36	Note 2
Green Wealth Investments Limited (Green Wealth)	Clear Precise Investments Limited (Clear Precise)	International investment	100	100	100	
Green Wealth Investments Limited (Green Wealth)	Vision Health Investments Limited (Vision Health)	International investment	100	100	100	Note 3
Clear Precise Investments Limited (Clear Precise)	Jiangsu Vizionfocus Inc.	R&D, design, and production of contact lens; wholesale and import and export of similar products of the above-mentioned products	80	80	80	

Note 1: As of March 31, 2026, the Company's management, after considering the absolute magnitude, relative size, and distribution of voting rights held compared to other shareholders, and given that all director positions of the subsidiary are held by the Company, determined that the Company possesses substantive ability to direct the relevant activities of Star Focus Inc., and therefore continues to classify it as a subsidiary.

Note 2: In response to the Company's overall operational development needs, the Company resolved through Board resolution in November 2024 to establish U.S. Subsidiary OCTI. Investment capital remittances were completed in January and August 2025, resulting in a 98.77% ownership interest. The subsidiary primarily engages in medical device sales.

Note 3: As of March 2026, the Company has not yet remitted investment funds and the subsidiary has no operational activities.

(II) Subsidiaries with significant non-controlling equity

Name of subsidiary	Shareholding and voting rights ratio held by non-controlling interests (%)		
	March 31, 2026	December 31, 2025	March 31, 2025
Jiangsu Vizionfocus Inc.	20.00	20.00	20.00

Please refer to Table 2 for information on principal places of business and countries of incorporation.

Name of subsidiary	Net income for the period distributed to non-controlling interests: January 1 to March 31, 2026	Net income for the period distributed to non-controlling interests: January 1 to March 31, 2025	Non-controlling interests: March 31, 2026	Non-controlling interests: December 31, 2025	Non-controlling interests: March 31, 2025
Jiangsu Vizionfocus Inc.	$ 18,043	$ 9,544	$413,350	$383,715	$333,256

The summarized financial information of Jiangsu Vizionfocus Inc. is based on the amount before writing off the intercompany transactions:

	March 31, 2026	December 31, 2025	March 31, 2025
Current assets	$ 1,083,454	$ 970,303	$ 809,503
Non-current assets	1,523,628	1,450,712	1,295,327
Current liabilities	(329,663)	(290,770)	(228,160)
Non-current liabilities	(210,669)	(211,669)	(210,388)
Equity	$ 2,066,750	$ 1,918,576	$ 1,666,282
Equity attributable to			
Owners of the Company	$ 1,653,400	$ 1,534,861	$ 1,333,026
Non-controlling interests of Jiangsu Vizionfocus Inc.	413,350	383,715	333,256
	$ 2,066,750	$ 1,918,576	$ 1,666,282

	January 1 to March 31, 2026	January 1 to March 31, 2025
Net operating revenue	$ 398,944	$ 234,982
Net income for the period	$ 90,214	$ 47,717
Other comprehensive income	-	-
Total comprehensive income	$ 90,214	$ 47,717
Net profit attributable to		
Owners of the Company	$ 72,171	$ 38,173
Non-controlling interests of Jiangsu Vizionfocus Inc.	18,043	9,544
	$ 90,214	$ 47,717

(To be Continued)

(Continued from previous page)

	January 1 to March 31, 2026	January 1 to March 31, 2025
Total comprehensive income attributable to		
Owners of the Company	$ 72,171	$ 38,173
Non-controlling interests of Jiangsu Vizionfocus Inc.	18,043	9,544
	$ 90,214	$ 47,717
Cash flow		
Operating activities	$ 149,068	$ 155,308
Investment activities	(38,685)	(118,962)
Financing activities	(4,390)	(4,523)
Effect of exchange rate changes	21,530	12,710
Net cash inflow	$ 127,523	$ 44,533

XI. Property, plant and equipment

January 1 to March 31, 2026

	Land	Machinery and equipment	Mold equipment	Transportation equipment	Office equipment	Leasehold improvements	Other equipment	Unfinished construction and equipment to be inspected	Total
Cost									
Balance on January 1, 2026	$ 705,898	$ 2,495,770	$ 146,823	$ 8,058	$ 32,864	$ 316,734	$ 48,581	$ 1,338,440	$ 5,093,168
Addition	-	88,208	7,941	-	1,510	968	1,397	251,949	351,973
Disposition	-	-	-	-	(27)	-	-	-	(27)
Exchange difference, net	-	33,836	2,370	45	328	4,473	391	5,832	47,275
Balance on March 31, 2026	705,898	2,617,814	157,134	8,103	34,675	322,175	50,369	1,596,221	5,492,389
Accumulated depreciation									
Balance on January 1, 2026	-	1,052,035	92,497	6,877	23,110	168,800	24,152	-	1,367,471
Depreciation expense	-	74,350	6,561	114	1,517	9,289	2,666	-	94,497
Disposition	-	-	-	-	(27)	-	-	-	(27)
Exchange difference, net	-	9,026	1,176	33	218	2,177	101	-	12,731
Balance on March 31, 2026	-	1,135,411	100,234	7,024	24,818	180,266	26,919	-	1,474,672
Net as of December 31, 2025	$ 705,898	$ 1,443,735	$ 54,326	$ 1,181	$ 9,754	$ 147,934	$ 24,429	$ 1,338,440	$ 3,725,697
Net as of March 31, 2026	$ 705,898	$ 1,482,403	$ 56,900	$ 1,079	$ 9,857	$ 141,909	$ 23,450	$ 1,596,221	$ 4,017,717

January 1 to March 31, 2025

	Land	Machinery and equipment	Mold equipment	Transportation equipment	Office equipment	Leasehold improvements	Other equipment	Unfinished construction and equipment to be inspected	Total
Cost									
Balance on January 1, 2025	$ 705,898	$ 1,997,948	$ 112,100	$ 7,630	$ 25,160	$ 303,450	$ 32,616	$ 832,306	$ 4,017,108
Addition	-	91,319	11,343	-	2,128	704	347	110,809	216,650
Disposition	-	(67)	-	-	-	-	(27)	-	(94)
Exchange difference, net	-	19,089	1,338	23	179	3,084	141	4,005	27,859
Balance on March 31, 2025	705,898	2,108,289	124,781	7,653	27,467	307,238	33,077	947,120	4,261,523
Accumulated depreciation									
Balance on January 1, 2025	-	781,222	68,618	6,020	18,763	132,117	14,894	-	1,021,634
Depreciation expense	-	63,649	5,472	230	1,062	8,892	2,077	-	81,382
Disposition	-	(67)	-	-	-	-	(27)	-	(94)
Exchange difference, net	-	4,400	571	23	119	1,160	50	-	6,323
Balance on March 31, 2025	-	849,204	74,661	6,273	19,944	142,169	16,994	-	1,109,245
Net as of March 31, 2025	$ 705,898	$ 1,259,085	$ 50,120	$ 1,380	$ 7,523	$ 165,069	$ 16,083	$ 947,120	$ 3,152,278

Property, plant and equipment are depreciated on a straight-line basis over the following useful lives:

Machinery and equipment	3 to 10 years
Mold equipment	2 to 5 years
Transportation equipment	4 to 5 years
Office equipment	3 to 7 years
Leasehold improvements	3 to 14 years
Other equipment	2 to 10 years

Please refer to Note 30 for the amount of property, plant and equipment pledged by the Company and its subsidiaries to secure borrowings.

XII. Lease agreement

(I) Right-of-use assets

	March 31, 2026	December 31, 2025	March 31, 2025
Book value of right-of-use assets			
Land	$ 1,456	$ 1,551	$ 1,836
Buildings	295,166	302,175	352,107
Machinery and equipment	121	162	284
	$296,743	$303,888	$354,227

	January 1 to March 31, 2026	January 1 to March 31, 2025
Addition of right-of-use assets	$ 1,624	$13,912
Depreciation expense of right-of-use assets		
Land	$ 95	$ 95
Buildings	13,219	12,698
Machinery and equipment	41	41
	$13,355	$12,834

Except for the additions and depreciation expense recognized as described above, neither the Company nor its subsidiaries had any material sublease transactions or impairment of right-of-use assets for the three months ended March 31, 2026 and 2025.

(II) Lease liabilities

	March 31, 2026	December 31, 2025	March 31, 2025
Book value of lease liabilities			
Current	$ 53,376	$ 52,301	$ 50,088
Non-current	$252,283	$260,143	$310,819

Discount rate interval (%) of lease liabilities is as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Land	1.605	1.605	1.605
Buildings	1.247～4.75	1.247～4.75	1.247～4.75
Machinery and equipment	1.023	1.023	1.023

(III) Important lease-in activities and terms and conditions

The Company and its subsidiaries leased offices, plants, machinery and equipment, and parking spaces, and the lease periods have gradually expired before the end of December 2034. Upon termination of the lease term, the Company and its subsidiaries have no preferential right to acquire the leased right-of-use assets, and it is agreed that the Company and its subsidiaries shall not sublease or transfer the subject of the lease, in whole or in part.

(IV) Other lease information

	January 1 to March 31, 2026	January 1 to March 31, 2025
Short-term and low-value lease expenses	$ 1,668	$ 915
Total cash outflows of all lease agreements (including short-term leases)	$ 16,874	$ 15,481

The Company and its subsidiaries have elected to apply the recognition exemption for leases of parking spaces and staff dormitories that qualify as short-term leases and other equipment that qualifies for low-value asset leases, and do not recognize right-of-use assets and lease liabilities for these leases.

XIII. Intangible assets

	March 31, 2026	December 31, 2025	March 31, 2025
Computer software	$ 5,215	$ 5,561	$ 5,303
Product certificate	101,115	78,777	63,269
Intangible assets under development	41,425	59,942	46,125
Other intangible assets (primarily consisting of customer relationships, customer lists, and trademark rights)	15,419	15,406	17,105
	$ 163,174	$ 159,686	$ 131,802

January 1 to March 31, 2026

	Computer software	Product certificate	Intangible assets under development	Other intangible assets	Total
Cost					
Balance on January 1, 2026	$ 26,291	$ 126,112	$ 59,942	$ 16,451	$ 228,796
Addition	622	-	6,163	-	6,785
Reclassification	-	24,894	(24,894)	-	-
Exchange difference, net	205	1,797	214	297	2,513
Balance on March 31, 2026	27,118	152,803	41,425	16,748	238,094
Accumulated amortization					
Balance on January 1, 2026	20,730	47,335	-	1,045	69,110
Amortization expense	1,005	3,538	-	263	4,806
Exchange difference, net	168	815	-	21	1,004
Balance on March 31, 2026	21,903	51,688	-	1,329	74,920
Net as of December 31, 2025	$ 5,561	$ 78,777	$ 59,942	$ 15,406	$ 159,686
Net as of March 31, 2026	$ 5,215	$ 101,115	$ 41,425	$ 15,419	$ 163,174

January 1 to March 31, 2025

	Computer software	Product certificate	Intangible assets under development	Other intangible assets	Total
Cost					
Balance on January 1, 2025	$ 21,641	$ 96,511	$ 47,584	$ -	$ 165,736
Addition	1,499	-	3,096	17,218	21,813
Reclassification	-	4,961	(4,961)	-	-
Exchange difference, net	130	848	406	163	1,547
Balance on March 31, 2025	23,270	102,320	46,125	17,381	189,096
Accumulated amortization					
Balance on January 1, 2025	16,802	36,258	-	-	53,060
Amortization expense	1,057	2,379	-	273	3,709
Exchange difference, net	108	414	-	3	525
Balance on March 31, 2025	17,967	39,051	-	276	57,294
Net as of March 31, 2025	$ 5,303	$ 63,269	$ 46,125	$ 17,105	$ 131,802

The above-mentioned intangible assets with finite useful lives are amortized on a straight-line basis based on the following useful lives:

Computer software	1 to 5 years
Product certificate	5 to 10 years
Other intangible assets	15 years

The amount prepaid by the Company and its subsidiaries to apply for the relevant product certificate are recognized as intangible assets under development and will be transferred to intangible assets - product certificate when the approval certificate is duly obtained.

XIV. Borrowings

(I) Short-term borrowings

	March 31, 2026	December 31, 2025	March 31, 2025
Bank credit	$ -	$ 20,000	$ -
Interest rate per annum (%)	-	1.7	-

(II) Long-term borrowings

	March 31, 2026	December 31, 2025	March 31, 2025
Credit loans			
Expiring successively before March 2035	$ 890,806	$ 846,588	$ 629,562
Secured borrowings			
Expiring successively by August 2027	419,880	419,880	419,880
	1,310,686	1,266,468	1,049,442
Less: Due within one year	114,942	136,685	155,279
Less: Recognized as deferred income – current (Note 24)	3,076	3,319	4,017
Less: Recognized as deferred income – non-current (Note 24)	12,648	11,755	9,102
	$ 1,180,020	$ 1,114,709	$ 881,044
Interest rate range (%)			
Credit loans	0.725～1.8	0.725～1.8	0.725～1.62
Secured borrowings	1.82	1.82	1.82

According to the loan agreements signed between the Company and Mega Bank, Chinatrust Bank and Taishin Bank, the relevant financial ratios and amounts of the semi-annual consolidated financial statements audited and certified by the CPA for the Company and its subsidiaries should comply with certain ratios. The aforementioned regulations are subject to review once every six months or annually, and the Company's consolidated financial statements for 2025 did not violate the aforementioned regulations.

Please refer to Note 30 for the status of joint guarantees and collateral provided for long-term borrowings by the Company and its subsidiaries.

XV. Notes payable and accounts payable

	March 31, 2026	December 31, 2025	March 31, 2025
Notes payable			
Arising from operations	$ -	$ 3,014	$ -
Accounts payable	$278,377	$250,187	$197,550

The Company and its subsidiaries have financial risk management policies to ensure that all payables are repaid within the pre-agreed credit terms.

XVI. Other payables

	March 31, 2026	December 31, 2025	March 31, 2025
Remuneration payable to employees and directors	$128,662	$100,028	$117,789
Payables for equipment	83,501	118,807	56,948
Payable insurance premiums and pensions	56,475	51,840	48,945
Salary payable	52,098	46,752	41,749
Bonus payable	30,064	82,009	26,412
Others (consumables, repairs, and miscellaneous purchases)	80,641	80,222	51,872
	$431,441	$479,658	$343,715

XVII. Post-employment benefit plan

The retirement benefit plan adopted by the Company and its domestic subsidiaries under the "Labor Pension Act" is a state-managed defined contribution plan. Under the Labor Pension Act, the Company makes monthly contributions to employees' individual pension accounts at 6% of their monthly salaries and wages.

According to the local laws and regulations, the subsidiaries in Mainland China are required to contribute a specific percentage of the salary cost to the relevant government departments.

The pension expense related to the defined benefit plans recognized for the three months ended March 31, 2026 and 2025 was calculated using the pension cost rates actuarially determined as of December 31, 2025 and 2024, and amounted to NT$505 thousand and NT$373 thousand, respectively.

XVIII. Equity

(I) Common stock capital

	March 31, 2026	December 31, 2025	March 31, 2025
Rated number of shares (thousand shares)	80,000	80,000	80,000
Authorized share capital	$800,000	$800,000	$800,000
Number of issued and fully paid shares (thousand shares)	58,709	58,528	58,045
Issued share capital	$587,087	$585,277	$580,447

During the three months ended March 31, 2026, the Company issued 181 thousand shares as a result of employees exercising stock options. The shares were issued at a weighted-average price of NT$77.97 per share. The excess of the issuance price over the par value amounting to NT$12,303 thousand was recognized under capital surplus－additional paid-in capital from share issuance.

During fiscal year 2025, the Company issued 603 thousand shares due to employees exercising stock options at a weighted average price of NT$45.81 per share issued at premium. The difference between the issue price and the par value of NT$21,593 thousand was recorded under capital surplus – premium on stock issuance.

From January 1 to March 31, 2025, the Company issued 120 thousand shares due to employees exercising stock options at a weighted average price of NT$114.41 per share issued at premium. The difference between issue price and par value of NT$12,529 thousand was recorded under capital surplus - premium on stock issuance.

(II) Capital reserve

	March 31, 2026	December 31, 2025	March 31, 2025
Can be used to offset losses, distribute cash or capitalize on share capital (Note 1)			
Premium from stock issuance	$ 1,859,517	$ 1,843,697	$ 1,829,914
Difference Between the Fair Value and Carrying Amount of the Consideration Paid or Received for the Acquisition or Disposal of Subsidiaries	29	29	29
From gifts and acceptances (Note 2)	1,800	1,800	1,800
Not to be used for any purpose			
Employee share warrants	2,322	5,839	9,590
	$ 1,863,668	$ 1,851,365	$1,841,333

Note 1: Such capital reserves may be used to make up for deficits, and may be used to distribute cash or capitalize on share capital when the Company has no losses. However, the capital reserves shall be limited to a certain percentage of the paid-in capital each year.

Note 2: Assets donated by the Company as received by the Chairman.

(III) Retained earnings and dividend policy

According to the Company's Articles of Incorporation, if there is a profit at the end of the year, it shall first pay taxes and make up for past losses and then distribute it as follows:

1. Set aside 10% as a legal reserve, unless the legal reserve reaches the amount of the Company's paid-in capital.
2. Provision or reversal of special reserve in accordance with the regulations of the competent authority.

3. The remainder is added to the accumulated undistributed earnings of the previous years as the earnings available for distribution, and the board of directors prepares an earnings appropriation proposal and submits it to the shareholders' meeting for resolution.

The Company pursues sustainable operations and stable management and development in line with the overall environment, industry growth characteristics, and the Company's long-term financial planning. The Company adopts a residual dividend policy where the annual fund needs are measured based on the Company's future capital budget planning. After the funds required for financing are reserved, the remaining earnings may be distributed in the form of cash dividends and stock dividends. The distribution steps are as follows:

1. Determine the optimal capital budget.
2. Determine the funds required for financing for the aforesaid capital budget.
3. Determine how much of the funds for financing are covered by retained earnings.
4. After an appropriate portion of the remaining earnings is retained depending on the operational needs, the remainder may be distributed to shareholders in the form of dividends. The amount to be distributed shall not be less than 10% of the Company's distributable earnings for the year, provided that the cash dividend shall not be less than 10% of the total dividends to be distributed.

The legal reserve can be used to make up for losses. When the company has no losses, the portion of the legal reserve exceeding 25% of the total paid-in capital can be allocated to capital and distributed in cash.

The Company's Board of Directors in March 2026 and shareholders' meeting in May 2025 proposed and resolved, respectively, the following appropriations of 2025 and 2024 earnings and cash dividends per share:

	Proposal for the distribution of earnings		Dividends per share (NTD)	
	2025	2024	2025	2024
Statutory Reserve	$ 74,043	$ 66,942		
Reversal of special reserve	-	(9,499)		
Cash dividends	409,694	322,641	$ 7	$ 5.57

The proposal for 2025 earnings distribution is pending resolution at the Annual Shareholders' Meeting expected to be held in May 2026.

(IV) Other equity

Exchange differences on translation of financial statements of foreign operations:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Opening balance	$ 29,448	$ 19,275
Exchange differences arising from the translation of net assets of foreign operations	47,129	27,620
Related income tax	(9,426)	(5,524)
Closing balance	$ 67,151	$ 41,371

(V) Non-controlling interests

	January 1 to March 31, 2026	January 1 to March 31, 2025
Opening balance	$ 424,027	$ 316,862
Net income for the period	26,730	8,585
Other comprehensive income in the current period		
Foreign Currency Translation Adjustment	11,601	6,859
Changes in non-controlling interests due to subsidiary capital increase (Note 25)	-	35,571
Increase in non-controlling interests from acquisition of subsidiaries	-	820
Closing balance	$ 462,358	$ 368,697

XIX. Revenue

	January 1 to March 31, 2026	January 1 to March 31, 2025
Revenue from contracts with customers		
Merchandise sales revenue	$1,025,643	$ 808,132
Others	5,084	2,403
	$1,030,727	$ 810,535

(I) Contract balance

	March 31, 2026	December 31, 2025	March 31, 2025	January 1, 2025
Notes and accounts receivable	$946,392	$891,838	$650,872	$641,421
Contract liabilities				
Sales of goods	$ 16,375	$ 21,318	$ 7,931	$ 4,384

The changes in contract liabilities were primarily due to timing differences between the satisfaction of performance obligations and customer payments for the three months ended March 31, 2026 and 2025, with no other significant changes during the periods.

The amounts of revenue recognized in the current period that were included in the opening contract liability balance:

Contract liabilities at the beginning of the year	January 1 to March 31, 2026	January 1 to March 31, 2025
Sales of goods	$20,341	$ 4,381

(II) Breakdown of revenue from customer contracts

January 1 to March 31, 2026

	Reporting department		
Type of income	Contact lens - injection molded sheet	Others	Total
Merchandise sales revenue	$ 1,025,643	$ -	$ 1,025,643
Other operating revenue	-	5,084	5,084
	$ 1,025,643	$ 5,084	$ 1,030,727

January 1 to March 31, 2025

	Reporting department		
Type of income	Contact lens - injection molded sheet	Others	Total
Merchandise sales revenue	$ 808,132	$ -	$ 808,132
Other operating revenue	-	2,403	2,403
	$ 808,132	$ 2,403	$ 810,535

XX. Net income before tax

Net income before tax includes the following items:

(I) Interest revenue

	January 1 to March 31, 2026	January 1 to March 31, 2025
Bank deposits	$ 2,251	$ 3,450
Others	17	14
	$ 2,268	$ 3,464

(II) Other income

	January 1 to March 31, 2026	January 1 to March 31, 2025
Government grant income	$ 1,037	$ 9,130
Others	1,688	1,061
	$ 2,725	$ 10,191

(III) Other gains and losses

	January 1 to March 31, 2026	January 1 to March 31, 2025
Net gain from foreign currency exchange	$ 13,630	$ 10,761
Gains from the disposal of property, plant and equipment	-	25
Others	(30)	23
	$ 13,600	$ 10,809

The above net foreign currency exchange gains and losses are detailed as follows:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Foreign exchange gain	$ 15,322	$ 11,815
Total foreign currency exchange losses	(1,692)	(1,054)
Net profit	$ 13,630	$ 10,761

(IV) Finance Costs

	January 1 to March 31, 2026	January 1 to March 31, 2025
Interest on bank borrowings	$ 5,590	$ 4,114
Interest on lease liabilities	2,189	2,561
Total interest expenses of financial liabilities at fair value through profit and loss	7,779	6,675
Less: Amount to be included in the cost of eligible assets	1,705	-
	$ 6,074	$ 6,675

Information on interest capitalization is as follows:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Amount of capitalized interest	$ 1,705	$ -
Interest capitalized interest rate (%)	1.62	-

(V) Depreciation and amortization

	January 1 to March 31, 2026	January 1 to March 31, 2025
Property, plant and equipment	$ 94,497	$ 81,382
Right-of-use assets	13,355	12,834
Intangible assets	4,806	3,709
	$ 112,658	$ 97,925
Depreciation expenses by function		
Operating cost	$ 101,318	$ 89,892
Operating expenses	6,534	4,324
	$ 107,852	$ 94,216
Amortization expenses by function		
Operating cost	$ 901	$ 931
Operating expenses	3,905	2,778
	$ 4,806	$ 3,709

(VI) Employee benefit expense

	January 1 to March 31, 2026	January 1 to March 31, 2025
Short-term employee benefits		
Salary	$ 194,944	$ 165,430
Labor and national health insurance	13,736	13,536
Others	15,926	11,420
	224,606	190,386
Post-employment benefits		
Defined contribution plan	10,749	3,368
Defined benefit plan (Note 17)	505	373
	$ 235,860	$ 194,127
Summary by function		
Operating cost	$ 165,910	$ 131,597
Operating expenses	69,950	62,530
	$ 235,860	$ 194,127

(VII) Remuneration to employees and directors

The company allocates employee and director remunerations based on pre-tax net income before distributions to employees and directors at rates ranging from 1% to 12% and up to 1.5%, respectively. However, if the company still has accumulated losses, it must first reserve amounts to cover these losses before allocating employee and director remunerations according to the aforementioned percentages.

Following amendments to the Securities and Exchange Act in August 2024, the Company has resolved at the 2025 shareholders' meeting to amend its articles of incorporation, stipulating that from the amount allocated for employee compensation, no less than 1% shall be allocated as compensation distributed to entry-level employees.

The estimated employee compensation and directors' remuneration for the three months ended March 31, 2026 and 2025 were as follows:

Amount	January 1 to March 31, 2026	January 1 to March 31, 2025
Remuneration to employees	$ 21,200	$ 22,735
Remuneration to directors	1,987	1,765

If there is still a change in the amount of the annual consolidated financial statements after the publication date, it will be treated as a change in the accounting estimate and will be adjusted and accounted for in the following year.

In March 2026 and 2025, the Company's Board of Directors approved the following amounts of employee compensation and directors' remuneration for 2026 and 2025, respectively:

Amount	2025	2024
Remuneration to employees	$ 72,090	$ 54,688
Remuneration to directors	6,267	5,633

There is no difference between the actual amount of employees' and directors' remuneration distributed for 2025 and 2024 and the amount recognized in the consolidated financial statements.

For information on employees' remuneration and remuneration of directors resolved by the Company's board of directors, please visit the Market Observation Post System of the Taiwan Stock Exchange.

XXI. Income tax

(I) Income tax recognized in profit or loss

The main components of income tax expense are as follows:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Current income tax		
Incurred in the current period	$ 60,454	$ 49,911
Deferred income tax		
Incurred in the current period	8,682	5,045
	$ 69,136	$ 54,956

(II) Income tax recognized in other comprehensive income

	January 1 to March 31, 2026	January 1 to March 31, 2025
Deferred income tax		
Foreign Currency Translation Adjustment	$ 9,426	$ 5,524

(III) Authorization of income tax

The income tax returns of the Company up to 2024 have been approved by the tax authorities.

XXII. Earnings per share

The net income and the weighted average number of ordinary shares used to calculate the earnings per share are as follows:

Net income for the period

	January 1 to March 31, 2026	January 1 to March 31, 2025
Net income attributable to owners of the Company	$214,777	$192,731

Number of shares (unit: thousand)

	January 1 to March 31, 2026	January 1 to March 31, 2025
Weighted average number of ordinary shares for calculation of basic earnings per share	58,672	58,004
Potential dilutive ordinary shares		
Remuneration to employees	419	332
Employee share warrants	68	589
Weighted average number of ordinary shares for calculation of diluted earnings per share	59,159	58,925

If the company chooses to distribute employee remunerations in either stock or cash, when calculating diluted earnings per share, it is assumed that remunerations will be paid in stock, and this potential common stock is included in the weighted average number of shares outstanding when it has a dilutive effect to compute diluted earnings per share. The dilutive effect of these potential ordinary shares will also be taken into account when calculating the diluted earnings per share before the number of shares to be distributed to employees in the following year.

XXIII. Share-based payment agreement

Employee stock option plan

In May 2021 and December 2022, the company's board of directors resolved to issue 1,700 thousand and 300 thousand stock options to employees, respectively. Each unit entitles the holder to subscribe for one ordinary share and is available to employees who meet specific eligibility criteria. The warrants have a lifespan of six years. The holders can exercise a certain proportion of their subscription rights starting two years after the issue date. Following the issuance of the warrants, if there are any changes in the issuance of the company's ordinary shares, the exercise price of the warrants will be adjusted according to the specified formula.

Information on employee stock options is as follows:

	January 1 to March 31, 2026		January 1 to March 31, 2025	
Employee share warrants	Unit (Thousands)	Weighted average exercise price (NTD)	Unit (Thousands)	Weighted average exercise price (NTD)
Shares outstanding at beginning of period	303		906	
Grants during the period	(181)	$ 77.97	(120)	$114.41
Shares outstanding at end of period	122	$ 79.89	786	$ 49.12
Executable at the end of period	122		54	

As of March 31, 2026, information on outstanding employee stock options is as follows:

Range of exercise price	Weighted average remaining contract term (years)
$28.06～118.4	1.88

The Company adopts the Black-Scholes valuation model for granting stock warrants to employees, and the inputs used in the valuation model are as follows:

	2022	2021
Grant-date stock price	NT$99.72	NT$29.26
Exercise price	NT$129.4	NT$30
Expected stock price volatility (%)	40.68～41.53	39.03～39.64
Expected duration (year)	4～4.5	4～5
Expected dividend yield	-	-
Expected subscription ratio (%)	100	100
Risk-free interest rate (%)	1.12～1.13	0.26～0.28

Compensation cost of NT$680 thousand was recognized for the three months ended March 31, 2025, with a corresponding credit to capital surplus－employee stock options.

For the three months ended March 31, 2026 and 2025, amounts of NT$3,517 thousand and NT$2,784 thousand, respectively, were reclassified from capital surplus－employee stock options to capital surplus－share premium upon the exercise of employee stock options.

XXIV. Government grants

The company has obtained government-subsidized loans with preferential interest rates under the ‘Welcoming Taiwanese Businesses to Invest Back in Taiwan Action Plan’, which are used for capital expenditures and working capital needs. The fair value of these loans is estimated based on the interest rates under normal conditions of the company. The difference between the fair value and the amount of the loans obtained is considered a government subsidy for low-interest loans and is recognized as deferred income:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Opening balance	$ 15,074	$ 12,570
Recognition of difference in fair value in current period	1,612	1,599
Recognized in current period (accounted for other income)	(962)	(1,050)
Closing balance	$ 15,724	$ 13,119

Book value of deferred income	March 31, 2026	December 31, 2025	March 31, 2025
Deferred revenue	$ 3,076	$ 3,319	$ 4,017
Long-term deferred revenue	12,648	11,755	9,102
	$ 15,724	$ 15,074	$ 13,119

XXV. Equity transactions with non-controlling interests - January 1 to March 31, 2025 only

In January 2025, the Company did not subscribe to subsidiary Star Focus Inc.'s cash capital increase in proportion to its shareholding, resulting in the shareholding percentage decreasing from 100% to 40.67%. Since the above transaction did not change the Company's control over the subsidiary, the Company treated it as an equity transaction. Related information is as follows:

	January 1 to March 31, 2025
Cash consideration received	$ 35,600
Amount of subsidiary's net asset carrying value to be transferred to non-controlling interests calculated based on relative change in equity interest	(35,571)
Equity transaction balance	$ 29

The Company's adjustment to the above equity transaction difference is as follows:

	January 1 to March 31, 2025
Capital reserve - the difference between the price of the subsidiary's equity actually acquired or disposed of and the book value	$ 29

XXVI. Non-cash transactions

For the three months ended March 31, 2026 and 2025, the Company and its subsidiaries engaged in the following non-cash investing activities:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Investment activities that affect both cash and non-cash items		
Increase in property, plant and equipment	$351,973	$216,650
Decrease (increase) of payables for equipment	35,306	(13,203)
Increase in prepayment for equipment	79,640	7,235
Capitalized interest	(1,705)	-
Amount of cash paid	$465,214	$210,682
Increase in intangible assets	$ 6,785	$ 20,993
Decrease in other payables	3,793	4,002
Amount of cash paid	$ 10,578	$ 24,995

XXVII. Capital risk management

The Company and its subsidiaries manage capital to ensure that they can optimize the balance of debt and equity to ensure the efficient use of capital and the smooth operation of the Company and subsidiaries under the premise of continuing to operate.

The company and its subsidiaries' capital structure consists of net debt and equity. The senior management regularly reviews the capital structure based on the current industry operational status and future development of the company, considering factors such as changes in the external environment. The review includes the cost of various types of capital and related risks, balancing the overall capital structure through issuing new shares, procuring new debt, and repaying existing debts.

XXVIII. Financial instruments

(I) Information on fair value - financial instruments not measured at fair value

The Company and its subsidiaries' management believe that the carrying amounts of financial assets and financial liabilities not measured at fair value approximate their fair values.

(II) Type of financial instruments

	March 31, 2026	December 31, 2025	March 31, 2025
Financial assets			
Measured at amortized cost (Note 1)	$ 2,152,587	$ 2,196,512	$ 2,297,981
Financial liabilities			
Measured at amortized cost (Note 2)	2,004,785	2,004,266	1,577,830

Note 1: The balance includes financial assets measured at amortized cost such as cash and cash equivalents, notes and accounts receivable, other receivables, other financial assets – current, and refundable deposits.

Note 2: The balance includes short-term borrowings, notes and accounts payable, other payables, long-term borrowings (including long-term borrowings due within one year), refundable deposits (classified under other non-current liabilities), and financial liabilities measured at amortized cost.

(III) Financial risk management objectives and policies

The main financial instruments of the Company and its subsidiaries include accounts receivable, long-term and short-term loans, accounts payable and lease liabilities. The financial management department provides services for each business unit and coordinates the operation of entering the domestic financial market. Extensive analysis of risk exposure and internal risk reports; monitoring and management of financial risks related to the operations of the Company and its subsidiaries. Such risks include market risk (including exchange rate risk and interest rate risk), credit risk and liquidity risk.

The significant financial activities of the Company and its subsidiaries are conducted by the Board of Directors in accordance with relevant regulations, internal control systems, and management policies. Internal audit personnel continuously review compliance with policies and risk exposure levels. The Company and its subsidiaries do not engage in transactions involving financial instruments (including derivative instruments) for speculative purposes.

1. Market risk

The main financial risks to which the Company and its subsidiaries are exposed are the risk of changes in foreign currency exchange rates (see (1) below) and the risk of changes in interest rates (see (2) below).

There has been no change to the Company's and subsidiaries' exposure to market risks of financial instruments and the management and measurement of such exposures.

(1) Exchange rate risk

The Company and its subsidiaries engage in activities such as sales and purchase transactions, capital expenditures, and equity investments that are denominated in non-functional currencies, resulting in exchange rate risk. The foreign exchange risk management of the Company and its subsidiaries manage and reduce risks by engaging in forward foreign exchange contract transactions, utilizing purchased foreign currency deposits, and foreign currency receivables and payables of the same category generated from transactions within the scope permitted by policies.

For the carrying amounts of monetary assets and monetary liabilities denominated in non-functional currencies of the Company and its subsidiaries at the balance sheet date, please refer to Note 32.

The Company and its subsidiaries were mainly affected by fluctuations in the exchange rates of the USD and CNY. The following table details a sensitivity analysis when the functional currency of the Group depreciates by 1% against the US dollar and the Chinese Yuan. The 1% sensitivity ratio

is used internally by the company to report exchange rate risks to senior management and represents management's assessment of the reasonably possible range of foreign exchange rate fluctuations. The sensitivity analysis only includes monetary items in USD and RMB outstanding.

	January 1 to March 31, 2026	January 1 to March 31, 2025
Impact of USD		
Net income before tax	$ 2,477	$ 3,029
Impact of RMB		
Net income before tax	2,331	1,654

Note: Mainly derived from the outstanding USD and RMB (including cash and cash equivalents, accounts receivable, accounts payable, and other payables) that are still outstanding at the end of the reporting period for cash flow hedging.

Management believes that sensitivity analysis cannot represent the inherent risk of exchange rates, as the foreign currency exposure at the balance sheet date does not reflect exposures during the period, and sales denominated in USD and RMB may vary with customer orders and economic cycles.

(2) Interest rate risk

As the Company and its subsidiaries borrow funds at floating interest rates, interest rate risk exposure arises. The Company and its subsidiaries manage the interest rate risk by maintaining an appropriate portfolio of floating interest rates.

The carrying amounts of financial assets and financial liabilities of the Company and its subsidiaries with exposure to the interest rate risk on the balance sheet date are as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Fair value interest rate risk			
Financial assets	$ 245,920	$ 519,828	$ 839,532
Financial liabilities	305,659	312,444	360,907
Cash flow interest rate risk			
Financial assets	931,197	766,119	780,779
Financial liabilities	1,294,962	1,271,394	1,036,323

The following sensitivity analysis is based on the interest rate risk exposure of the non-derivative instruments at the balance sheet date. For liabilities with floating interest rates, the analysis method is based on the assumption that the amount of liabilities outstanding on the balance sheet date is outstanding throughout the reporting period. The rate of change used by the Company and subsidiaries to report interest rates to management is increased or decreased by 1%, which also represents management's assessment of the reasonably possible range of interest rates.

If interest rates on financial liabilities had increased/decreased by 1%, with all other variables held constant, the Company's profit before tax for the three months ended March 31, 2026 and 2025 would have decreased/increased by NT$3,237 thousand and NT$2,591 thousand, respectively.

2. Credit risk

Credit risk refers to the risk of financial loss to the Company and its subsidiaries due to the counterparty's default on contractual obligations. As of the balance sheet date, the maximum credit risk exposure of the Company and its subsidiaries that may cause financial losses due to the counterparty's failure to perform its obligations is the book value of financial assets recognized in the balance sheet.

All of the company and its subsidiaries' trading partners are companies with good creditworthiness. Business units grant trading credit limits based on the results of each credit assessment, and they regularly track the collection of receivables. In recent years, there have been very few actual cases of bad debts, and thus no significant credit risks are anticipated.

The company and its subsidiaries' receivables are significantly concentrated with several clients who engage in similar commercial activities and have similar economic characteristics. Consequently, their ability to fulfill contractual obligations is similarly affected by economic or other conditions, leading to a significant concentration of credit risk. The net accounts receivable of customers with significant concentration of credit risk are as follows:

Customer name	March 31, 2026	December 31, 2025	March 31, 2025
Company A	$ 112,193	$ 157,542	$ 169,949
Company B	109,516	138,716	103,705
Company C	109,060	112,417	19,231
Company D	98,053	65,844	27,833

3. Liquidity risk

The Company and its subsidiaries manage and maintain sufficient cash position to support the Company's operations and mitigate the impact of cash flow fluctuations. They also monitor the use of bank financing facilities and ensure compliance with the terms of the loan contract.

Bank borrowings are an important source of liquidity for the Company and its subsidiaries. As of March 31, 2026, December 31, 2025 and March 31, 2025, the Company and its subsidiaries had unused bank credit facilities of NT$4,687,242 thousand, NT$4,749,492 thousand and NT$4,851,734 thousand, respectively. Accordingly, there was no liquidity risk arising from any inability to obtain sufficient funding to meet contractual obligations.

The following table shows the non-derivative financial liabilities of the Company and its subsidiaries. The analysis is based on the remaining contractual maturity of the agreed repayment period, and is prepared based on the undiscounted cash flow of the earliest possible date on which repayment may be required (including interest and principal cash flows).

The bank borrowings that the Company and its subsidiaries may be required to repay immediately are serialized within the earliest period in the following table, regardless of the possibility of the bank executing the right immediately. The maturity analysis of other non-derivative financial liabilities is based on the agreed repayment date preparation.

March 31, 2026

	Within 1 year	1 to 5 years	More than 5 years	Total
Non-interest-bearing liabilities	$ 709,818	$ 5	$ -	$ 709,823
Instruments with floating interest rates	133,589	920,711	332,347	1,386,647
Lease liabilities	61,452	170,760	108,302	340,514
	$ 904,859	$1,091,476	$ 440,649	$2,436,984

Further information on the maturity analysis of lease liabilities is as follows:

	Less than 1 year	1 to 5 years	5 to 10 years	10 to 15 years
Lease liabilities	$ 61,452	$ 170,760	$ 108,302	$ -

December 31, 2025

	Within 1 year	1 to 5 years	More than 5 years	Total
Non-interest-bearing liabilities	$ 732,859	$ 13	$ -	$ 732,872
Instruments with floating interest rates	173,823	893,044	288,879	1,355,746
Lease liabilities	60,482	174,575	113,497	348,554
	$ 967,164	$1,067,632	$ 402,376	$2,437,172

Further information on the maturity analysis of lease liabilities is as follows:

	Less than 1 year	1 to 5 years	5 to 10 years	10 to 15 years
Lease liabilities	$ 60,482	$ 174,575	$ 113,497	$ -

March 31, 2025

	Within 1 year	1 to 5 years	More than 5 years	Total
Non-interest-bearing liabilities	$ 541,265	$ 242	$ -	$ 541,507
Instruments with floating interest rates	166,582	841,833	76,728	1,085,143
Lease liabilities	59,776	199,518	148,361	407,655
	$ 767,623	$1,041,593	$ 225,089	$2,034,305

Further information on the maturity analysis of lease liabilities is as follows:

	Less than 1 year	1 to 5 years	5 to 10 years	10 to 15 years
Lease liabilities	$ 59,776	$ 199,518	$ 148,361	$ -

XXIX. Related party transactions

(I) Names of related parties and their relationships

Name of related party	Relationship with the Company and its subsidiaries
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd (Jiangsu Yuyue)	Substantive related party
Jiangsu No.1 Garden Investment Co., Ltd.	Substantive related party
Jiangsu Joyea Co., Ltd. (Jiangsu Joyea)	Substantive related party

(II) Operating revenue

Presentation account	Name of related party	January 1 to March 31, 2026	January 1 to March 31, 2025
Sales revenue	Substantive related party	$ 100	$ -

Revenue from sales of goods primarily relates to the sale of contact lenses. Transaction prices and terms do not differ materially from those with unrelated parties.

(III) Closing balance

Presentation account	Category/Name of related party	March 31, 2026	December 31, 2025	March 31, 2025
Accounts receivable	Jiangsu Yuyue	$ 10,810	$ 10,388	$ -
Prepayment for equipment	Jiangsu Joyea	$ 40,522	$ 44,061	$ 19,020
Refundable deposits	Jiangsu Yuyue	$ 7,221	$ 7,014	$ 7,134
Other payables	Substantive related party	$ 2,837	$ 1,753	$ 1,795

(IV) Acquisition of property, plant and equipment

Category/ Name of related party	January 1 to March 31, 2026	January 1 to March 31, 2025
Proceeds from acquisition		
Jiangsu Joyea	$ 2,272	$ 6,323

The Company and its subsidiaries have not purchased similar property, plant and equipment from non-related parties, so the transaction prices cannot be compared, and there is no significant difference in payment terms compared to general manufacturers.

(V) Lease agreement

Presentation account	Name of related party	March 31, 2026	December 31, 2025	March 31, 2025
Lease liabilities (including current and non-current)	Jiangsu Yuyue	$158,001	$157,782	$190,355

Category/Name of related party	January 1 to March 31, 2026	January 1 to March 31, 2025
Interest expense		
Jiangsu Yuyue	$ 1,612	$ 1,934

The subsidiary has leased a plant from Jiangsu Yuyue since October 2019. The lease period expires in December 2034. The rent is calculated based on the floor area (in square feet) and fixed lease payments are paid on a quarterly basis in accordance with the lease contract.

(VI) Remuneration of key management personnel

	January 1 to March 31, 2026	January 1 to March 31, 2025
Short-term employee benefits	$ 20,100	$ 15,077
Post-employment benefits	162	189
	$ 20,262	$ 15,266

(VII) Other related party transactions

Other expenses

Category/Name of related party	January 1 to March 31, 2026	January 1 to March 31, 2025
Jiangsu Joyea	$ 402	$ 7

These represent repair and related expenses paid by the subsidiaries.

XXX. Pledged assets

The Company and its subsidiaries have provided the following assets as collateral for short-term and long-term credit facilities and customs guarantee facilities:

	Book value		
	March 31, 2026	December 31, 2025	March 31, 2025
Land	$ 705,898	$ 705,898	$ 705,898
Other financial assets	2,615	2,548	2,287
	$ 708,513	$ 708,446	$ 708,185

XXXI. Significant contingent liabilities and unrecognized contractual commitments

As of March 31, 2026, the Company and its subsidiaries had entered into contracts for

the purchase of property, plant and equipment with a total contract value of approximately NT$2,851,592 thousand, of which NT$1,124,991 thousand had not yet been recognized in the financial statements.

XXXII. Significant information on assets and liabilities denominated in foreign currencies

The following information is summarized and expressed in foreign currencies other than the functional currencies of the Company and each entity. The exchange rates disclosed refer to the rates at which these foreign currencies are converted to the functional currency. Financial assets and liabilities denominated in foreign currencies with significant impact are as follows:

Unit: Each foreign currency in thousands

	Foreign currency	Exchange rate		Carrying amount
March 31, 2026				
Monetary item - foreign currency assets				
USD	$ 8,444	31.995	(USD:NTD)	$ 270,155
RMB	51,094	4.629	(RMB:NTD)	236,516
JPY	60,988	0.2005	(JPY:NTD)	12,228
Non-monetary items of assets denominated in foreign currencies				
Subsidiaries accounted for using the equity method				
USD	1,302	31.995	(USD:NTD)	41,660
RMB	357,189	4.629	(RMB:NTD)	1,653,426
Monetary item foreign currency liabilities				
USD	599	31.995	(USD:NTD)	19,180
USD	104	6.9194	(USD:CNY)	3,324
RMB	740	4.629	(RMB:NTD)	3,424
JPY	59,491	0.2005	(JPY:NTD)	11,928
December 31, 2025				
Monetary item - foreign currency assets				
USD	8,233	31.430	(USD:NTD)	258,753
RMB	48,095	4.496	(RMB:NTD)	216,235
JPY	7,585	0.2008	(JPY:NTD)	1,523
Non-monetary items of assets denominated in foreign currencies				
Subsidiaries accounted for using the equity method				
USD	1,424	31.430	(USD:NTD)	41,660
RMB	341,389	4.496	(RMB:NTD)	1,534,886

(To be Continued)

(Continued from previous page)

	Foreign currency	Exchange rate		Carrying amount
Monetary item foreign currency liabilities				
USD	$ 621	31.430	(USD:NTD)	$ 19,509
USD	104	7.0288	(USD:CNY)	3,296
RMB	1,459	4.496	(RMB:NTD)	6,558
JPY	9,656	0.2008	(JPY:NTD)	1,939
March 31, 2025				
Monetary item - foreign currency assets				
USD	9,710	33.205	(USD:NTD)	322,422
RMB	36,308	4.573	(RMB:NTD)	166,035
JPY	13,763	0.2227	(JPY:NTD)	3,065
Non-monetary items of assets denominated in foreign currencies				
Subsidiaries accounted for using the equity method				
USD	1,349	33.205	(USD:NTD)	44,777
RMB	291,505	4.573	(RMB:NTD)	1,333,052
Monetary item foreign currency liabilities				
USD	517	33.205	(USD:NTD)	17,169
USD	71	7.1782	(USD:CNY)	2,320
RMB	133	4.573	(RMB:NTD)	610

The Company and its subsidiaries recognized net foreign exchange gains of NT$13,630 thousand and NT$10,761 thousand for the three months ended March 31, 2026 and 2025, respectively. As foreign currency transactions involve a variety of functional currencies, it is impracticable to disclose exchange gains and losses by each individual foreign currency that has a significant effect.

XXXIII. Disclosures in notes

(I) Significant transactions and (II) Information on investees

1. Loans to others: None.
2. Endorsements/guarantees for others: None.
3. Material holdings of marketable securities at the end of the period (excluding investments in subsidiaries, associates and joint ventures): None.
4. Total purchases from or sales to related parties amounting to at least NT$100 million or 20% of the paid-in capital: None.
5. Receivables from related parties amounting to at least NT$100 million or 20% of the paid-in capital: None.
6. Information on investees: Please refer to Table 1.
7. Business relationships and material transactions between the parent company and its subsidiaries, as well as among the subsidiaries: Please refer to Table 3.

(III) Mainland China Investment Information

1. For information regarding investees in Mainland China, including the investee name, principal business activities, paid-in capital, investment method, capital remittance, shareholding percentage, current-period profit or loss, recognized investment income or loss, carrying amount of the investment at the end of the period, repatriated investment income, and the investment limit in Mainland China, please refer to Table 2.

2. Any of the following significant transactions with investee companies in mainland China, either directly or indirectly through a third party, and their prices, payment terms, and unrealized gains or losses:

   (1) There were no purchases requiring disclosure of amounts, percentages, and ending balances of related payables.

   (2) There were no sales requiring disclosure of amounts, percentages, and ending balances of related receivables.

   (3) The amount of property transactions and the amount of the resulting gain or loss: None.

   (4) The balance and purpose of endorsements/guarantees for bills: None.

   (5) There were no financings requiring the disclosure of highest balance, ending balance, interest rate range, and total interest for the current period.

   (6) Other transactions with significant impacts on current period income or financial position, such as the rendering or receipt of services: Please refer to Table 3.

XXXIV. Department information

The information provided to the chief operating decision-maker for allocating resources and evaluating segment performance, with emphasis on each type of product or service delivered or provided. The operating segments of the Company and its subsidiaries shall be reported as follows:

- VIZIONFOCUS

  The main business items are the manufacturing of medical equipment, machinery and equipment, optical instruments, precision instruments and international trading and other consulting services.

- Jiangsu Vizionfocus Inc.

  The main business includes R&D, design and production of contact lenses, wholesale and import and export of similar products of the above products.

- Others - For the subsidiaries of the consolidated entity as the operating segment, please refer to the descriptions in Note 10.

(III) Segment revenues and operating results

The revenue and operating results of the Company and its subsidiaries are analyzed by reportable segment as follows:

	VIZIONFOCUS	Jiangsu Vizionfocus Inc.	Others	Adjustments and write-offs	Consolidated
January 1 to March 31, 2026					
Revenue from customers other than the parent company and subsidiaries	$ 560,956	$ 398,164	$ 71,607	$ -	$1,030,727
Revenue from parent company and subsidiaries	57,118	780	-	(57,898)	-
Total revenue	$ 618,074	$ 398,944	$ 71,607	$ (57,898)	$1,030,727
Departmental interest	$ 174,186	$ 102,051	$ 14,435	$ 7,452	$ 298,124
Interest revenue	864	1,273	131	-	2,268
Other income	8,442	1,656	79	(7,452)	2,725
Other gains and losses	13,595	104	(99)	-	13,600
Finance Costs	(4,424)	(1,612)	(38)	-	(6,074)
Share of Profit (Loss) of Subsidiaries Accounted for Using the Equity Method	74,312	-	144,342	(218,654)	-
Net income before tax	266,975	103,472	158,850	(218,654)	310,643
Income tax expense	52,198	13,258	3,680	-	69,136
Net income for the period	$ 214,777	$ 90,214	$ 155,170	$ (218,654)	$ 241,507
January 1 to March 31, 2025					
Revenue from customers other than the parent company and subsidiaries	$ 561,321	$ 234,933	$ 14,281	$ -	$ 810,535
Revenue from parent company and subsidiaries	40,630	49	-	(40,679)	-
Total revenue	$ 601,951	$ 234,982	$ 14,281	$ (40,679)	$ 810,535
Segment profit (loss)	$ 194,361	$ 46,310	$ (6,616)	$ 4,428	$ 238,483
Interest revenue	2,137	1,247	80	-	3,464
Other income	5,818	8,801	-	(4,428)	10,191
Other gains and losses	10,848	(39)	-	-	10,809
Finance Costs	(4,734)	(1,934)	(7)	-	(6,675)
Share of Profit (Loss) of Subsidiaries Accounted for Using the Equity Method	32,589	-	76,346	(108,935)	-
Net income before tax	241,019	54,385	69,803	(108,935)	256,272
Income tax expense	48,288	6,668	-	-	54,956
Net income for the period	$ 192,731	$ 47,717	$ 69,803	$ (108,935)	$ 201,316

Departmental profit or loss refers to the profit earned by each department. This measured amount is provided to the chief operating decision-maker for allocating resources to segments and evaluating their performance.

(IV) Departmental total assets and liabilities

	March 31, 2026	December 31, 2025	March 31, 2025
Segment assets			
VIZIONFOCUS	$ 6,440,775	$ 6,139,518	$ 5,554,126
Jiangsu Vizionfocus Inc.	2,607,082	2,421,015	2,104,830
Others	3,501,675	3,235,981	2,798,938
Adjustments and write-offs	(5,110,319)	(4,735,404)	(4,114,093)
Consolidated total assets	$ 7,439,213	$ 7,061,110	$ 6,343,801
Departmental liabilities			
VIZIONFOCUS	$ 2,189,681	$ 2,155,017	$ 1,797,624
Jiangsu Vizionfocus Inc.	540,332	502,439	438,548
Others	70,920	53,903	28,837
Adjustments and write-offs	(75,172)	(58,777)	(46,407)
Consolidated total liabilities	$ 2,725,761	$ 2,652,582	$ 2,218,602

VIZIONFOCUS INC. and subsidiaries
Information on investees
January 1 to March 31, 2026

Table 1

Unit: NTD Thousand
(unless otherwise stated)

Name of Investment Company	Name of investee	Location of the area	Main business items	Initial investment amount		Held at end of period			Profit or loss for the current period of investee companies (Note)	Investment profit or loss recognized during the current period (Note)	Notes
				End of current period	End of last year	Number of shares	Percentage (%)	Carrying amount			
The Company	Green Wealth Investments Limited (Samoa)	Samoa	International investment	$ 1,097,607	$ 1,097,607	35,692,609	100	$ 1,653,426	$ 72,171	$ 72,171	
The Company	Star Focus Inc.	Taiwan	Medical device sales	24,400	24,400	2,440,000	40.67	23,081	14,722	5,987	
The Company	Optical Connection Technology Inc.	USA	Medical device sales	64,607	64,607	2,000,000	98.77	37,107	(3,894)	(3,846)	
Green Wealth Investments Limited (Samoa)	Clear Precise Investments Limited (Samoa)	Samoa	International investment	1,097,607	1,097,607	35,692,609	100	1,653,426	72,171	72,171	

Note: All have been eliminated when preparing the consolidated financial statements.

VIZIONFOCUS INC. and subsidiaries
Mainland China Investment Information
January 1 to March 31, 2026

Table 2

Unit: NTD Thousand
(unless otherwise stated)

Name of investee company in Mainland China	Main business items	Paid-up capital	Investment method (Note 1)	Accumulated investment amount remitted from Taiwan at the beginning of the period	Investment amount remitted or recovered in the current period		Accumulated investment amount remitted from Taiwan at the beginning of the period	Net income of investees for the period	The Company's shareholding ratio in direct or indirect investments (%)	Investment gains recognized in current period	Book value of investment at the end of the period	Repatriated investment income up to the current period	Notes
					Remitted	Recovered							
Jiangsu Vizionfocus Inc.	R&D, design, and production of contact lens; wholesale and import and export of similar products of the above-mentioned products.	$ 741,566	(2)	$ 1,097,607	$ -	$ -	$ 1,097,607	$ 90,214	80	$ 72,17	$1,653,400	$ -	Note 2 & Note 3

Name of Investment Company	The accumulated amount remitted from Taiwan to invest in mainland China as of the end of the current period:	Amount of investment approved by the Investment Commission, Ministry of Economic Affairs	Limit of the Company's investment in Mainland China (Note 4)
Jiangsu Vizionfocus Inc.	$ 1,097,607	$ 1,184,248	$ -

Note 1: Investment methods are divided into the following three types. It is sufficient to indicate the type of investment:
(1) Direct investment in Mainland China.
(2) Reinvest in Mainland China through a company in a third region.
(3) Any other means.

Note 2: All have been eliminated when preparing the consolidated financial statements.

Note 3: Recognized and disclosed based on the Company's reviewed financial statements by its certified public accountants.

Note 4: This is in accordance with Point 3 of the "Principles for Reviewing Investments or Technical Cooperation in Mainland China," revised and issued on August 29, 2008, under Order Jing-Shen-Zi No. 09704604680. Our company has obtained a certificate from the Industrial Development Bureau of the Ministry of Economic Affairs, confirming compliance with the operational scope required for headquarters, thereby exempting it from any upper limits on investments in Mainland China.

VIZIONFOCUS INC. and subsidiaries
Business relationships and material transactions between the parent company and its subsidiaries
January 1 to March 31, 2026

Table 3

Unit: NTD Thousand
(unless otherwise stated)

Serial number	Trader's Name	Trading counterpart	Relationship with the counterparty	Transactions with each other			
				Subject Matters	Amount	Trading terms and conditions	As a percentage of consolidated revenue or total assets (%)
0	The Company	Jiangsu Vizionfocus Inc.	Subsidiary	Service revenue	$ 16,714	As stipulated in the contract	1.62
0	The Company	Jiangsu Vizionfocus Inc.	Subsidiary	Other operating revenue	2,994	As stipulated in the contract	0.29
0	The Company	Jiangsu Vizionfocus Inc.	Subsidiary	Royalty income	7,452	As stipulated in the contract	0.72
0	The Company	Jiangsu Vizionfocus Inc.	Subsidiary	Accounts receivable	19,970	As stipulated in the contract	0.27
0	The Company	Star Focus Inc.	Subsidiary	Sales revenue	35,347	As stipulated in the contract	3.43
0	The Company	Star Focus Inc.	Subsidiary	Accounts receivable	37,114	As stipulated in the contract	0.50
0	The Company	Optical Connection Technology Inc.	Subsidiary	Sales revenue	1,314	As stipulated in the contract	0.13